Taking proton pump inhibitors alongside tyrosine kinase inhibitors is associated with an increased mortality risk in older cancer patients, research indicates.
Presenting author Fausto Castagnetti discusses the results of their study assessing the best score to predict outcomes in older patients with chronic myeloid leukaemia (4:17).
The tyrosine kinase inhibitor dasatinib is effective and well tolerated as a first- or second-line therapy for children with chronic myeloid leukemia in the chronic phase, research confirms.